Press Release

June 02, 2022
1 min read

Memo Therapeutics examines treatment for BK polyomavirus in kidney transplant recipients


Press Release

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Memo Therapeutics AG announced the initiation of a phase 1 clinical study to examine MTX-005 against BK polyomavirus infection among kidney transplant patients.

“MTX-005 could be a game-changer for patients who are currently seriously underserved. The antibody possesses a 100 [times] more potent neutralization capacity than benchmark antibodies and we are encouraged by the feedback by key opinion leaders, which has been overwhelmingly positive,” Jürgen Beck, MD, MBA, chief medical officer of Memo Therapeutics AG, said in the release.

According to the release, MTX-005 is a therapeutic antibody candidate that neutralizes all strains of BK polyomavirus at low concentrations. BK polyomavirus infections are triggered from immunosuppression in 40% to 50% of kidney transplant recipients and can lead to serious complications. Currently, there is no disease- modifying therapy to solve this issue aside from lowering immunosuppression.

The phase 1, single-blind, partially randomized, placebo-controlled study will measure the safety, tolerability and pharmacokinetics of IV doses of MTX-005 in up to 56 healthy adults.

“With 50,000 kidney transplant procedures carried out in the U.S. and Europe alone, MTX-005 addresses a large and rapidly growing market, with an estimated size well beyond $1 billion,” Karsten Fischer, PhD, CEO of Memo Therapeutics AG, said in the release. “We look forward to reporting phase 1 clinical data for our best and potentially first-in-class antibody in the first half of 2023.”